Mayne to acquire North American rights to SuperGen's Nipent and SurfaceSafe for $34 million

By Lisa Kerner

Charlotte, N.C., June 21 - Mayne Pharma Ltd. has signed a definitive agreement to acquire the North American rights to Nipent (pentostatin for injection) and SurfaceSafe from SuperGen, Inc. for a total of $34 million, including a $14 million upfront payment and milestone payments.

Nipent is a treatment for hairy cell leukemia and SurfaceSafe is used to decontaminate surfaces where chemotherapy is mixed or administered.

Mayne will acquire all product rights, patents, registrations, trademarks, inventories and relevant supplier and customer contracts related to the two products.

In addition, the companies are negotiating additional agreements for mitomycin, a cytotoxic cancer therapeutic, for the U.S. market as well as any SuperGen rights outside of the United States.

"We are encouraged by Mayne Pharma's commitment to the oncology market and the continuing development of the Nipent franchise," SuperGen president and chief executive officer James S. Manuso said in a company news release.

"The added financial strength this transaction affords will further enable SuperGen to rapidly develop and commercialize our targeted therapeutics."

Based in Dublin, Calif., SuperGen develops therapies for solid tumors and hematological malignancies.

Located in Melbourne, Australia, Mayne is a specialty pharmaceutical company focused on oncology products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.